Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × tremelimumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 23 Thoracic 18 Genitourinary 17 Head & Neck 15 Dermatologic 14 Breast 10 Other solid neoplasm 6 Gynecologic 5 Sarcoma 3 Lymphoid 2 Endocrine 2 NET 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 15 Octreotide 8 lutetium Lu 177 dotatate 7 Temozolomide 6 lanreotide 5 Sunitinib 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 pasireotide 4 gallium Ga 68 dotatate 4 Data Collection 4 3-Iodobenzylguanidine 4 Magnetic Resonance Spectroscopy 3 Etoposide 3 Carboplatin 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pembrolizumab 2 pazopanib 2 fosbretabulin 2 fluorodopa F 18 2 avelumab 2 arginyllysine 2 Sorafenib 2 Single Photon Emission Computed Tomography Computed Tomography 2 Pemetrexed 2 PM 01183 2 Irinotecan 2 Ga(III)-DOTATOC 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡